State Street’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-189,721
Closed -$11.4M – 4539
2021
Q1
$11.4M Buy
189,721
+90,048
+90% +$3.26M ﹤0.01% 2677
2020
Q4
$1.48M Buy
99,673
+33,390
+50% +$465K ﹤0.01% 3468
2020
Q3
$760K Buy
+66,283
New +$1.13M ﹤0.01% 3503

State Street's PAND Position: Q2 2021 in Review

State Street sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 189,721 shares — an estimated $11.4M sold.

State Street first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $11.4M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • State Street reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • State Street sold 189,721 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $11.4M.
  • State Street first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • State Street's Pandion Therapeutics Inc. Common Stock position peaked at $11.4M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on State Street's 13F filing for Q2 2021, filed 16 Aug 2021.